What it is claimed to help
These are the uses attached to Larazotide acetate in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Randomised controlled human trials exist. Not necessarily approved, and not necessarily positive.
Extensive and instructive. Phase 2 trials in celiac disease showed symptom benefit and drove enormous interest. The phase 3 CeDLara trial was stopped for futility in 2022 after an interim analysis. This is the clearest example on the site of a peptide with promising early human data that did not survive a proper trial.
How it is supposed to work
Zonulin antagonist that tightens intestinal epithelial tight junctions, acting locally in the gut lumen with almost no systemic absorption.
Safety
Well tolerated across trials — the problem was efficacy, not safety.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- Leffler DA et al. Larazotide phase 2b, Gastroenterology 2015
- 9 Meters Biopharma CeDLara phase 3 discontinuation announcement, 2022
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.